Liliana M. Rogozea

Food, Dietary Supplement, and Gut Microbiome Interactions in Oral Anticancer Therapy: Mechanisms, Clinical Consequences, and Management

BACKGROUND: The shift toward oral targeted therapies and immune checkpoint inhibitors (ICIs) in oncology has introduced pharmacokinetic variability driven by food-drug interactions (FDIs), which can cause therapeutic failure or increased toxicity. AREAS OF UNCERTAINTY: FDI effect...